Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential

Summary

The relation between coagulation and atherosclerosis has been extensively described, pointing towards a hypercoagulable state in patients with atherosclerosis, especially in young individuals. However, not all studies were conclusive. It is known that the metabolic syndrome (MetS), a risk factor for coronary artery disease (CAD), is related to a higher incidence of thrombo-embolic events. We hypothesised that individuals with CAD at a young age and MetS have an increased prothrombotic potential. It was the study objective to analyse the endogenous thrombin potential (ETP) and related thrombin generation parameters in patients with CAD before the age of 51 in men and 56 in women with and without MetS features and their healthy first-degree relatives. In this case-control study we included 118 CAD patients and 50 first-degree relatives (controls). Parameters of thrombin generation were obtained with calibrated automated thrombinography. An adjusted general linear model (GLM) showed a positive association between the peak thrombin levels and the presence of CAD at a young age. Based on the NCEP criteria we divided our patient group in CAD patients with and without MetS, and compared them to the controls without MetS. We showed that CAD patients with MetS have increased ETP levels, both in comparison with healthy first-degree relatives and with CAD patients without MetS. There were no differences in ETP between patients without MetS and healthy controls. In conclusion, this study shows that individuals with CAD at a young age and MetS features have an increased prothrombotic potential, compared to CAD patients without MetS.

Keywords

Atherosclerosis - hypercoagulability - metabolic disorders - thrombin

• References

• 1 Willeit P, Thompson A, Aspelund T. et al. Haemostatic factors and risk of coronary heart disease in general populations: New prospective study and updated meta-analysis. PLoS ONE 2013; 8: e55157
• 2 Danesh J, Lewington S, Thompson S. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
• 3 Mannucci PM, Asselta R, Duga S. et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J. Thromb Haemost 2010; 8: 2116-2121.
• 4 Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group.. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-1122.
• 5 Loeffen R, Spronk HMH, Ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J. Thromb Haemost 2012; 10: 1207-1216.
• 6 Borissoff JI, Joosen Ia, Versteylen MO. et al. Accelerated In Vivo Thrombin Formation Independently Predicts the Presence and Severity of CT Angiographic Coronary Atherosclerosis. JACC Cardiovasc Imag 2012; 5: 1201-1210.
• 7 Carcaillon L, Alhenc-Gelas M, Bejot Y. et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol 2011; 31: 1445-1451.
• 8 Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957.
• 9 Ageno W, Prandoni P, Romualdi E. et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 1914-1918.
• 10 Ay C, Tengler T, Vormittag R. et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-380.
• 11 Third Report of the National Cholesterol Education Program (NCEP).. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
• 12 Georgiou D, Budoff MJ, Kaufer E. et al. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol 2001; 38: 105-110.
• 13 Hemker HC, Giesen P, AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
• 14 Spronk HMH, Dielis AWJH, De Smedt E. et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100: 362-364.
• 15 NIH Guidelines.. Cholesterol - at a glance. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf.
• 16 Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S. et al. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
• 17 Ye Z, Liu EHC, Higgins JPT. et al. Articles Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet 2006; 367: 651-658.
• 18 Danesh J, Lewington S, Thompson SG. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
• 19 Giannitsis E, Siemens HJ, Mitusch R. et al. Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999; 68: 269-274.
• 20 Henareh L, Jogestrand T, Agewall S. Prothrombin fragment 1 + 2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. Thromb Res 2009; 124: 526-530.
• 21 Páramo Ja, Orbe J, Beloqui O. et al. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 2004; 35: 1085-1089.
• 22 Smid M, Dielisa WJH, Winkens M. et al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011; 9: 450-456.
• 23 Cimenti C, Mangge H, Haidl H. et al. Thrombin generation in severely obese children. J Thromb Haemost 2006; 4: 1834-1836.
• 24 Fritsch P, Kleber M, Rosenkranz A. et al. Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis 2010; 212: 650-655.
• 25 Ay L, Kopp H-P, Brix J-M. et al. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost 2010; 8: 759-765.
• 26 Sanchez C, Poggi M, Morange P-E. et al. Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status. Arterioscler Thromb Vasc Biol 2012; 32: 2394-2404.
• 27 Folsom AR, Wu KK, Davis CE. et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
• 28 Balleisen L, Bailey J, Epping PH. et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479.
• 29 Barazzoni R, Zanetti M, Davanzo G. et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000; 85: 3121-3125.
• 30 Morishita E, Asakura H, Jokaji H. et al. Hypercoagulability and high lipopro-tein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 7-14.
• 31 Franchini M, Targher G, Montagnana M. et al. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res 2008; 122: 727-735.
• 32 Carvalho de Sousa J, Bruckert E, Giral P. et al. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 1989; 19: 125-130.
• 33 Sakkinen PA, Wahl P, Cushman M. et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
• 34 Anand SS, Yi Q, Gerstein H. et al. Relationship of metabolic syndrome and fibri-nolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-425.
• 35 Al-Hamodi Z, Ismail IS, Saif-Ali R. et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol 2011; 10: 23.
• 36 Mertens I, Verrijken A, Michiels JJ. et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes 2006; 30: 1308-1314.
• 37 Angelico F, Alessandr C, Ferro D. et al. Enhanced soluble CD40L in patients with metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-1174.
• 38 Sommeijer DW, MacGillavry MR, Meijers JC. et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 2004; 27: 468-473.
• 39 Dielis a WJH, Castoldi E, Spronk HMH. et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
• 40 Tchaikovski SN, Van Vliet HAAM, Thomassen MCLGD. et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 98: 1350-1356.
• 41 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2: 1954-1959.
• 42 Santagostino E, Mancuso ME, Tripodi A. et al. Severe haemophilia with mild bleeding phenotype: molecular characterisation and global coagulation profile. J Thromb Haemost 2010; 8: 737-43.